Results 31 to 40 of about 61,613 (221)

CTDSP1 inhibitor rabeprazole regulates DNA-PKcs dependent topoisomerase I degradation and irinotecan drug resistance in colorectal cancer.

PLoS ONE, 2020
Irinotecan specifically targets topoisomerase I (topoI), and is used to treat various solid tumors, but only 13-32% of patients respond to the therapy.
Hiroya Matsuoka, Koji Ando, Emma J Swayze, Elizabeth C Unan, Joseph Mathew, Quingjiang Hu, Yasuo Tsuda, Yuichiro Nakashima, Hiroshi Saeki, Eiji Oki, Ajit K Bharti, Masaki Mori   +11 more
doaj   +1 more source

First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI) [PDF]

, 2012
The objective of this pilot clinical study was to assess the safety, technical feasibility, pharmacokinetic (PK) profile and tumour response of DC Bead™ with irinotecan (DEBIRI™) delivered by intra-arterial embolisation for the treatment of metastatic ...
Hammerstingl, Renate Maria, Mack, Martin G., Gallus, Christof, Eichler, Katrin, Gruber-Rouh, Tatjana, Vogl, Thomas J., Zangos, Stephan   +6 more
core   +1 more source

Determination of Irinotecan enantiomer impurity in Irinotecan Hydrochloride API by using reverse-phase liquid chromatography [PDF]

, 2023
To evaluate and quantify Irinotecan (R-enantiomer) / Irinotecan related compound D in Irinotecan hydrochloride trihydrate API, a high stereo-specific liquid chromatography technique was developed and validated.
Srinivas P, Vijay, Vijay Srinivas P, Manjusha K, Gana, Vinukonda, Anjaneyulu, Gana Manjusha K, Anjaneyulu Vinukonda   +5 more
core   +1 more source

Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia [PDF]

, 2007
Background: Irinotecan-based second-line chemotherapy of metastatic colorectal cancer (CRC) is effective, it might, however, be contraindicated in cases of severe liver dysfunction due to advanced liver metastases.
Moosmann, Nicolas, Schulz, Christoph, Laessig, Dorit, Michaely, Henrik Jakob, Heinemann, Volker   +4 more
core   +1 more source

Monitoring of Irinotecan in Human Plasma: Sensitive Fluorescent Nanogels by Molecular Imprinting [PDF]

, 2019
A series of fluorescent molecularly imprinted nanogels to detect irinotecan (CPT11) were prepared and characterized. A set of amino acids and napthalimide polymerisable derivatives allowed to obtain polymers as soluble fluorescent nanoparticles by high ...
Cristina, Forzato, Valentina, Iacuzzi, Paola, Posocco, Martina, Tommasini, Elena, Marangon, Marina, Resmini, Giuseppe, Toffoli, Federico, Berti, Elena, Pellizzoni, Paolo, Bertoncin   +9 more
core   +2 more sources

A Retrospective Analysis of the Effect of Irinotecan-Based Regimens in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

Frontiers in Oncology, 2021
BackgroundAt present, patients with metastatic breast cancer (MBC) have few treatment options after receiving anthracyclines and taxanes. Studies have shown that irinotecan has modest systemic activity in some patients previously treated with ...
Jiaojiao Suo, Xiaorong Zhong, Xiaorong Zhong, Ping He, Ping He, Hong Zheng, Hong Zheng, Tinglun Tian, Tinglun Tian, Xi Yan, Xi Yan, Ting Luo, Ting Luo   +12 more
doaj   +1 more source

Deciphering the Formulation-Dependent Neurotoxicity of Irinotecan: An Integrated Pharmacovigilance and Mechanistic Study. [PDF]

J Biochem Mol Toxicol
Irinotecan is a key chemotherapeutic agent, but its neurotoxicity limits its utility. Observed differences in neurotoxicity between conventional and liposomal formulations are poorly characterized mechanistically.
Shen C, Ma W, Lu J, Tang Y, Cao W.
europepmc   +2 more sources

A phase I evaluation of the effect of curcumin on dose‐limiting toxicity and pharmacokinetics of irinotecan in participants with solid tumors

Clinical and Translational Science, 2022
Curcumin inhibits UDP‐glucuronyltransferases, a primary metabolic pathway for cancer chemotherapeutic agents like irinotecan. Concurrent administration of both agents may exacerbate irinotecan toxicity.
Olumide B. Gbolahan, Bert H. O’Neil, Autumn J. McRee, Hanna K. Sanoff, John K. Fallon, Philip C. Smith, Anastasia Ivanova, Dominic T. Moore, Julie Dumond, Gary N. Asher   +9 more
doaj   +1 more source

Liposomal Irinotecan Shows a Larger Therapeutic Index than Non-liposomal Irinotecan in Patient-Derived Xenograft Models of Pancreatic Cancer

Oncology and Therapy, 2023
Introduction Liposomal irinotecan promotes controlled sustained release of irinotecan (CPT-11), therefore, we hypothesize that the therapeutic index (quantitative measurement of the relative efficacy/safety ratio of a drug) will be higher for liposomal ...
Sandrine Barbier, Benjamin Beaufils, Ricardo de Miguel, Melissa Reyre, Yannick Le Meitour, Andreanne Lortie, Marc Hillairet de Boisferon, Sophie Chaumeron, Anne Espirito, Lina Fossati, Pauline Lagarde, Stephan Klinz, Arunthathi Thiagalingam, Stéphane Lezmi, Florence Meyer-Losic   +14 more
doaj   +1 more source

Risk factors for irinotecan-induced hepatotoxicity: a retrospective cohort study. [PDF]

Front Oncol
Background Irinotecan is a potent chemotherapeutic agent used as a neoadjuvant in colorectal cancer liver metastasis and significantly enhances five-year survival rates.
Alherz FA, Alnakhli AM, Alqarni AM, Alshammari AF, Ruwayi AM, Alyamani RM, Al-Salloum H, Al-Yamani MJ, Shuweihdi F.   +8 more
europepmc   +2 more sources